Restriction of parallel trade: EU Court of Justice Advocate General Trstenjak suggests to the Court of Justice to confirm the Court of First Instance’s judgment in a case regarding restrictions on parallel trade in medicines needing only a substitution of reasons related to the notion of anticompetitive object (GlaxoSmithKline)

*This article is an automatic translation of the original article, provided here for your convenience. Read the original article. Advocate General Trstenjak presented today, 30 June 2009, his forms of order sought in Joined Cases C-501/06 P, C-513/06 P, C-515/06 P and C-519/06 concerning the practice of restricting parallel trade in medicines, but this time in its Article 81(1). It will be remembered that in this case of control by pharmaceutical producers of parallel trade in medicines between Spain, where the administration sets maximum prices, and other Member States, in particular the United Kingdom, where prices are at a higher level, the Tribunal of First Instance of the European Communities has partially annulled, by judgment of 27 September 2006, the Commission's decision